Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Collegium Pharmaceutical Inc (NASDAQ: COLL) closed at $37.87 up 4.79% from its previous closing price of $36.14. In other words, the price has increased by $4.79 from its previous closing price. On the day, 0.54 million shares were traded. COLL stock price reached its highest trading level at $37.89 during the session, while it also had its lowest trading level at $36.04.
Ratios:
For a deeper understanding of Collegium Pharmaceutical Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.93 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.91. For the most recent quarter (mrq), Quick Ratio is recorded 1.10 and its Current Ratio is at 1.18. In the meantime, Its Debt-to-Equity ratio is 4.10 whereas as Long-Term Debt/Eq ratio is at 3.81.
On July 30, 2024, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $47.
Jefferies Upgraded its Hold to Buy on June 07, 2024, whereas the target price for the stock was revised from $41 to $44.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 08 ’25 when Freund John Gordon sold 11,659 shares for $34.36 per share. The transaction valued at 400,641 led to the insider holds 23,129 shares of the business.
Heffernan Michael Thomas bought 10,328 shares of COLL for $332,269 on Jul 09 ’25. On Jul 08 ’25, another insider, Heffernan Michael Thomas, who serves as the Former Director of the company, bought 790 shares for $31.38 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, COLL now has a Market Capitalization of 1192984448 and an Enterprise Value of 1922569600. As of this moment, Collegium’s Price-to-Earnings (P/E) ratio for their current fiscal year is 36.56, and their Forward P/E ratio for the next fiscal year is 4.83. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 22.02. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.69 while its Price-to-Book (P/B) ratio in mrq is 5.15. Its current Enterprise Value per Revenue stands at 2.719 whereas that against EBITDA is 5.116.
Stock Price History:
The Beta on a monthly basis for COLL is 0.60, which has changed by 0.10408163 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, COLL has reached a high of $42.29, while it has fallen to a 52-week low of $23.23. The 50-Day Moving Average of the stock is 21.99%, while the 200-Day Moving Average is calculated to be 24.97%.
Shares Statistics:
For the past three months, COLL has traded an average of 313.28K shares per day and 475000 over the past ten days. A total of 31.55M shares are outstanding, with a floating share count of 30.18M. Insiders hold about 4.21% of the company’s shares, while institutions hold 118.59% stake in the company. Shares short for COLL as of 1753920000 were 4215754 with a Short Ratio of 13.46, compared to 1751241600 on 4354200. Therefore, it implies a Short% of Shares Outstanding of 4215754 and a Short% of Float of 16.03.
Earnings Estimates
Currently, 4.0 analysts are dedicated to thoroughly evaluating and rating the performance of Collegium Pharmaceutical Inc (COLL) in the stock market.The consensus estimate for the next quarter is $2.23, with high estimates of $2.66 and low estimates of $2.0.
Analysts are recommending an EPS of between $10.47 and $6.91 for the fiscal current year, implying an average EPS of $7.92. EPS for the following year is $7.85, with 5.0 analysts recommending between $10.76 and $6.65.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $190.97M this quarter.It ranges from a high estimate of $194.14M to a low estimate of $189.6M. As of the current estimate, Collegium Pharmaceutical Inc’s year-ago sales were $159.3MFor the next quarter, 5 analysts are estimating revenue of $199.11M. There is a high estimate of $212.8M for the next quarter, whereas the lowest estimate is $187.7M.
A total of 5 analysts have provided revenue estimates for COLL’s current fiscal year. The highest revenue estimate was $759.6M, while the lowest revenue estimate was $743M, resulting in an average revenue estimate of $753.73M. In the same quarter a year ago, actual revenue was $631.45MBased on 5 analysts’ estimates, the company’s revenue will be $777.76M in the next fiscal year. The high estimate is $789.7M and the low estimate is $751.5M.
